汇宇制药-W
(688553)
| 流通市值：66.82亿 | | | 总市值：82.39亿 |
| 流通股本：3.44亿 | | | 总股本：4.24亿 |
| 报告期 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 流动资产: | | | | |
| 货币资金 | 1,981,653,478.45 | 2,328,244,429.04 | 2,226,834,716.33 | 2,033,607,564.78 |
| 应收票据及应收账款 | 56,459,503.79 | 55,547,492.94 | 57,032,323.59 | 56,148,303.14 |
| 其中：应收票据 | 280,600 | 1,632,394.95 | - | - |
| 应收账款 | 56,178,903.79 | 53,915,097.99 | 57,032,323.59 | 56,148,303.14 |
| 预付款项 | 40,183,521.56 | 19,934,582.35 | 26,787,628.18 | 24,866,619.97 |
| 其他应收款合计 | 14,567,998.86 | 2,529,110.22 | 6,485,111.18 | 6,592,857.27 |
| 存货 | 202,748,808.4 | 159,919,087.79 | 165,519,595.25 | 161,705,304.73 |
| 其他流动资产 | 92,604,779.83 | 89,581,217.04 | 85,316,392.3 | 85,044,996.95 |
| 流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 流动资产合计 | 3,151,505,632.34 | 3,344,348,217.96 | 3,059,569,944.91 | 2,829,559,824.92 |
| 非流动资产: | | | | |
| 长期股权投资 | 89,664,618.91 | 89,664,618.91 | 93,080,402.09 | 93,034,879.94 |
| 其他非流动金融资产 | 69,529,440.76 | 76,074,128.45 | 270,313,336.59 | 154,810,214.83 |
| 固定资产 | 971,304,250.14 | 986,203,573.79 | 647,897,922.53 | 625,148,028.83 |
| 在建工程 | 504,657,219.83 | 528,714,584.02 | 799,251,576.95 | 811,048,942.64 |
| 使用权资产 | 943,264.75 | 1,561,036.81 | 2,605,669.55 | 3,223,441.61 |
| 无形资产 | 60,283,351.95 | 60,566,483.1 | 60,506,722.17 | 61,066,076.91 |
| 开发支出 | 30,930,605.69 | 25,703,405.18 | 23,476,294.69 | 27,143,778.67 |
| 长期待摊费用 | 844,949.97 | 1,075,390.89 | 1,305,831.81 | 1,536,272.73 |
| 递延所得税资产 | 39,347,363.11 | 24,469,013.75 | 48,850,734.05 | 48,755,025.01 |
| 其他非流动资产 | 30,433,439.35 | 27,246,305.7 | 42,333,241.95 | 55,989,092.94 |
| 非流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 非流动资产合计 | 1,797,938,504.46 | 1,821,278,540.6 | 1,989,621,732.38 | 1,881,755,754.11 |
| 资产平衡项目 | 0 | 0 | 0 | 0 |
| 资产总计 | 4,949,444,136.8 | 5,165,626,758.56 | 5,049,191,677.29 | 4,711,315,579.03 |
| 流动负债: | | | | |
| 短期借款 | 410,339,715.79 | 580,280,993.09 | 675,298,538.89 | 550,306,972.24 |
| 应付票据及应付账款 | 160,230,313.59 | 197,033,339.03 | 116,563,022.11 | 121,194,402.4 |
| 其中：应付票据 | 14,920,355 | 3,994,945 | - | - |
| 应付账款 | 145,309,958.59 | 193,038,394.03 | 116,563,022.11 | 121,194,402.4 |
| 预收款项 | 29,357.83 | 386,694.5 | - | - |
| 合同负债 | 65,003,153.99 | 54,329,772.89 | 25,605,697.67 | 20,632,802.14 |
| 应付职工薪酬 | 27,998,526.54 | 38,915,481.35 | 34,098,684.74 | 28,679,725.98 |
| 应交税费 | 4,837,667.88 | 6,419,729.36 | 9,700,358.51 | 6,279,855.93 |
| 其他应付款合计 | 252,952,983.12 | 256,190,338.9 | 262,897,622.96 | 236,115,026.63 |
| 一年内到期的非流动负债 | 1,654,203.23 | 1,640,520.02 | 2,547,659.37 | 2,544,675.8 |
| 其他流动负债 | 1,555,726.35 | 1,551,955.97 | 671,866.88 | 795,503.43 |
| 流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 流动负债合计 | 924,601,648.32 | 1,136,748,825.11 | 1,127,383,451.13 | 966,548,964.55 |
| 非流动负债: | | | | |
| 租赁负债 | - | - | 11,220 | 737,609.6 |
| 递延收益 | 73,868,254.22 | 48,979,993.52 | 21,213,361.81 | 22,139,856.63 |
| 递延所得税负债 | 4,882,360.19 | 6,517,538.15 | 23,270,955.83 | 4,916,325.92 |
| 非流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 非流动负债合计 | 78,750,614.41 | 55,497,531.67 | 44,495,537.64 | 27,793,792.15 |
| 负债平衡项目 | 0 | 0 | 0 | 0 |
| 负债合计 | 1,003,352,262.73 | 1,192,246,356.78 | 1,171,878,988.77 | 994,342,756.7 |
| 所有者权益(或股东权益): | | | | |
| 实收资本(或股本) | 423,600,000 | 423,600,000 | 423,600,000 | 423,600,000 |
| 资本公积 | 2,487,295,700.22 | 2,487,295,700.22 | 2,485,318,082.86 | 2,485,318,082.86 |
| 减:库存股 | 30,020,576.71 | 30,020,576.71 | 30,020,576.71 | 30,020,576.71 |
| 其他综合收益 | -8,844,351.05 | -8,241,372.69 | -7,199,757.67 | -8,979,121.36 |
| 盈余公积 | 152,803,980.38 | 152,803,980.38 | 113,912,463.67 | 113,912,463.67 |
| 未分配利润 | 927,980,229.38 | 953,606,714.68 | 894,460,320.83 | 732,321,352.83 |
| 归属于母公司股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 归属于母公司股东权益合计 | 3,952,814,982.22 | 3,979,044,445.88 | 3,880,070,532.98 | 3,716,152,201.29 |
| 少数股东权益 | -6,723,108.15 | -5,664,044.1 | -2,757,844.46 | 820,621.04 |
| 股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 股东权益合计 | 3,946,091,874.07 | 3,973,380,401.78 | 3,877,312,688.52 | 3,716,972,822.33 |
| 负债和股东权益合计 | 4,949,444,136.8 | 5,165,626,758.56 | 5,049,191,677.29 | 4,711,315,579.03 |
| 公告日期 | 2025-04-26 | 2025-04-26 | 2024-10-26 | 2024-08-27 |
| 审计意见(境内) | | 标准无保留意见 | | |